Last updated: September 8, 2026
Pasireotide pamoate is marketed by Novartis as Signifor LAR, a long-acting intramuscular formulation for acromegaly and Cushing’s disease. Its commercial profile is defined by a narrow endocrine market, specialist administration, durable dosing, and clinically important hyperglycemia that limits use relative to competing somatostatin receptor ligands and cortisol-pathway drugs.
Novartis does not report Signifor LAR revenue as a standalone line in its current financial disclosures. The product is therefore best evaluated through indication growth, competitive share, dosing economics, regulatory protection, and the timing of potential generic or follow-on entry rather than through a fully disclosed product-level revenue series.
What is pasireotide pamoate and how is it used?
Pasireotide pamoate is the long-acting injectable form of pasireotide. Signifor LAR is administered by deep intramuscular injection, generally once every four weeks, after dose selection and tolerability assessment.
| Attribute |
Signifor LAR |
| Active ingredient |
Pasireotide pamoate |
| Sponsor |
Novartis |
| Drug class |
Multireceptor ligand somatostatin analog |
| Primary receptors |
High affinity for somatostatin receptor subtype 5, with activity at other receptor subtypes |
| Route |
Intramuscular injection |
| Dosing interval |
Every four weeks |
| Main indications |
Acromegaly and Cushing’s disease |
| U.S. regulatory status |
FDA-approved product |
| Commercial positioning |
Specialist, second-line or later-line endocrine therapy |
Pasireotide differs from octreotide and lanreotide because it has particularly strong activity at somatostatin receptor 5. That receptor profile supports efficacy in selected patients but also contributes to a high risk of treatment-related hyperglycemia. The U.S. prescribing information identifies hyperglycemia and diabetes as major safety concerns and recommends glucose monitoring before and during treatment.[1]
When did Signifor LAR receive FDA approval?
The regulatory sequence created two distinct commercial opportunities.
| Date |
Regulatory milestone |
| December 2012 |
FDA approved subcutaneous Signifor for Cushing’s disease in patients for whom pituitary surgery was not an option or had not been curative.[2] |
| December 2014 |
FDA approved Signifor LAR for acromegaly in patients who had an inadequate response to surgery or were not candidates for surgery.[3] |
| October 2018 |
FDA expanded Signifor LAR to adults with Cushing’s disease for whom pituitary surgery was not an option or had not been curative.[4] |
The LAR formulation expanded the product from a multiple-daily-injection Cushing’s treatment into a depot product with monthly administration. That change improved convenience but did not remove the drug’s glucose-management burden.
European approval also covers acromegaly and Cushing’s disease, subject to the European product information and national reimbursement systems.[5]
How large is the pasireotide pamoate market?
Pasireotide pamoate occupies a niche within two orphan or near-orphan endocrine markets.
Acromegaly market
Acromegaly treatment is dominated by:
- Long-acting octreotide;
- Long-acting lanreotide;
- Pegvisomant;
- Oral and investigational somatostatin-pathway products;
- Surgery and radiotherapy in selected patients.
Somatostatin analogs remain common first-line medical treatments after surgery or when surgery is unsuitable. Pasireotide LAR is generally considered for patients with inadequate biochemical control on first-generation somatostatin analogs, particularly when the receptor profile suggests a potential response.
Its market opportunity is constrained by three factors:
- First-generation somatostatin analogs have established physician familiarity and broad reimbursement.
- Hyperglycemia can make pasireotide unsuitable for patients with diabetes or substantial metabolic risk.
- Pegvisomant can provide an alternative mechanism for patients whose insulin-like growth factor 1 remains uncontrolled.
The product’s commercial value therefore depends less on total acromegaly prevalence than on the smaller population with persistent disease after standard somatostatin analog treatment.
Cushing’s disease market
Cushing’s disease is a smaller but more specialized market. Transsphenoidal pituitary surgery remains the preferred curative approach when feasible. Drug treatment is used when surgery is contraindicated, unsuccessful, delayed, or followed by recurrence.
Pasireotide competes with:
- Osilodrostat, marketed as Isturisa by Recordati;
- Mifepristone, marketed as Korlym by Corcept Therapeutics;
- Ketoconazole and metyrapone;
- Cabergoline in selected patients;
- Repeat surgery or radiotherapy;
- Other investigational pituitary-directed and adrenal-directed therapies.
Pasireotide has a differentiated mechanism because it suppresses ACTH secretion through somatostatin receptor signaling. Its commercial disadvantage is the frequency and severity of glucose abnormalities. Osilodrostat attacks cortisol synthesis directly and has become a major competitor in medically managed Cushing’s disease.
What is the financial trajectory of pasireotide pamoate?
Novartis does not currently provide a separate, regularly reported revenue line for Signifor or Signifor LAR in the same way it reports major products such as Entresto, Cosentyx, Kisqali, and Kesimpta.[6]
The financial trajectory can be characterized as follows:
| Period |
Commercial interpretation |
| 2012-2014 |
Initial launch through subcutaneous Signifor and subsequent LAR entry in acromegaly |
| 2015-2017 |
Expansion in acromegaly, with revenue supported by the monthly formulation |
| 2018-2020 |
Cushing’s disease label expansion increased addressable use, but competition and glucose-related discontinuation limited acceleration |
| 2021 onward |
Mature niche-brand profile with limited public product-level financial disclosure and increasing competitive pressure |
The LAR formulation likely became the principal commercial product because monthly administration is more practical than repeated daily subcutaneous injections. However, the product’s growth potential is structurally capped by its indication size and its safety profile.
The principal financial risks are:
- Reimbursement restrictions requiring failure of other therapies;
- Reduced persistence in patients who develop hyperglycemia;
- Competition from osilodrostat in Cushing’s disease;
- Competition from pegvisomant and established somatostatin analogs in acromegaly;
- Potential price pressure after patent and regulatory protection declines;
- Limited expansion into broader endocrine indications.
Revenue estimates published by third-party market-research firms should be treated cautiously because they often combine pasireotide formulations, geographies, or indications and may not distinguish product sales from market size.
How does pasireotide compare with competing endocrine drugs?
| Product |
Main target or mechanism |
Primary commercial advantage |
Main limitation |
| Signifor LAR |
Somatostatin receptor ligand, strong SSTR5 activity |
Monthly administration and differentiated pituitary activity |
Hyperglycemia and diabetes risk |
| Sandostatin LAR |
Octreotide, somatostatin analog |
Long commercial history and broad physician use |
Incomplete biochemical control in some patients |
| Somatuline Depot |
Lanreotide |
Monthly administration and established acromegaly use |
Similar class limitations and incomplete control |
| Somavert |
Pegvisomant, growth hormone receptor antagonist |
Effective IGF-1 control through a different mechanism |
Daily injection and monitoring burden |
| Isturisa |
Osilodrostat, cortisol synthesis inhibitor |
Direct cortisol reduction in Cushing’s disease |
Adrenal insufficiency and steroidogenic monitoring |
| Korlym |
Glucocorticoid receptor antagonist |
Useful for hyperglycemia associated with endogenous Cushing’s |
Does not directly measure cortisol control; drug-interaction burden |
Pasireotide’s best competitive position is in patients who need a pituitary-directed therapy, have failed or cannot use standard somatostatin analogs, and can be managed safely despite metabolic risk.
What patents protect pasireotide pamoate?
The pasireotide estate has multiple possible protection layers:
- Active-ingredient and composition claims;
- Pasireotide pamoate salt claims;
- Long-acting injectable depot formulation claims;
- Manufacturing and crystal-form claims;
- Method-of-use claims for acromegaly;
- Method-of-use claims for Cushing’s disease;
- Drug-device, administration, or dosing claims where listed.
The relevant U.S. reference product is listed in FDA’s Orange Book under Signifor and Signifor LAR entries. Patent listings and expiry dates can change through patent-term adjustment, pediatric extensions, terminal disclaimers, litigation outcomes, and regulatory listing corrections.[7]
The original pasireotide active-ingredient protection is materially older than the LAR formulation and indication patents. The commercial barrier is therefore more likely to unwind in stages than on a single date. A generic manufacturer would need to assess whether it can enter with:
- A conventional pasireotide injection;
- A pamoate depot formulation;
- A comparable long-acting injectable suspension;
- A product that avoids unexpired formulation or method-of-use claims.
When does pasireotide lose exclusivity?
The drug’s earliest U.S. regulatory exclusivity periods have expired or are no longer the primary commercial barrier. The remaining protection is more likely to depend on listed patents, formulation complexity, and the practical requirements for demonstrating pharmaceutical equivalence to a long-acting injectable.
A precise commercial loss-of-exclusivity date cannot be reduced to the original FDA approval date. Signifor LAR has separate regulatory and patent considerations from the earlier subcutaneous product. The FDA Orange Book and USPTO records are the controlling sources for current listed patents and expiration calculations.[7,8]
Are there Paragraph IV challenges to Signifor LAR?
No major public Paragraph IV litigation has established a broad generic-entry pathway for pasireotide pamoate comparable to high-volume small-molecule products. The absence of a prominent challenge is commercially meaningful because long-acting injectable products impose higher development and manufacturing costs than oral generics.
A future ANDA applicant would face several practical issues:
- Demonstrating equivalence for a depot suspension;
- Matching particle-size and release characteristics;
- Establishing injectable-product quality and sterility;
- Addressing complex manufacturing controls;
- Navigating method-of-use patents for endocrine indications;
- Managing a small market with limited volume potential.
A Paragraph IV filing could still occur before all relevant patents expire, but the expected return is less attractive than for a large primary-care product.
What generic entry risks exist?
The most likely entry scenarios are staged rather than immediate.
Scenario 1: No near-term generic entry
Novartis retains effective protection, and the small patient population does not justify the cost of a competing depot product. Signifor LAR remains a protected specialist brand.
Scenario 2: Limited indication-specific entry
A generic or follow-on entrant challenges selected method-of-use or formulation patents but initially limits commercial exposure to indications not covered by enforceable claims. This would require careful labeling and patent analysis.
Scenario 3: Full long-acting injectable competition
A competitor successfully resolves patent and regulatory barriers and launches a comparable monthly pasireotide pamoate product. Price erosion could be significant, but total market expansion would remain limited.
The most credible commercial risk is not an abrupt collapse caused by ordinary tablet-style generic substitution. It is gradual erosion from competing endocrine therapies, tighter reimbursement, and eventual specialist-brand substitution.
How strong is the pasireotide patent estate?
The estate is stronger in formulation and delivery than in basic active-ingredient protection because the product’s commercial differentiation is the monthly depot injection. Long-acting injectable claims can create a meaningful barrier when they cover composition, release profile, particle characteristics, or manufacturing steps.
Its weaknesses are equally clear:
- The active ingredient is an established molecule;
- The indications are narrow;
- Clinical differentiation is mixed;
- Competitors address the same diseases through different mechanisms;
- A small patient population limits the economic value of prolonged litigation.
Overall, pasireotide has a moderate commercial patent position but a more challenging market position. Patent durability alone is unlikely to generate substantial growth without better tolerability, broader reimbursement, or evidence supporting earlier use.
What litigation, licensing, and settlement issues affect the product?
No major publicly reported settlement has reshaped the pasireotide market in the manner seen for high-revenue cardiovascular, oncology, or immunology products. Novartis remains the central commercial rights holder for Signifor and Signifor LAR.
The principal legal questions are likely to concern:
- Orange Book listing validity;
- Formulation and depot patents;
- Method-of-use enforcement;
- Label-carve-out strategies;
- Patent-term calculations;
- Potential manufacturing-process disputes.
There is no major disclosed licensing transaction that has materially altered the ownership or commercial control of Signifor LAR.
What is the outlook for pasireotide pamoate revenue?
The base-case outlook is stable to declining in nominal terms rather than high growth.
Revenue support comes from:
- Chronic treatment duration;
- Monthly administration;
- Specialist use in difficult-to-control disease;
- Lack of a simple oral substitute for all eligible patients;
- Continued use in both acromegaly and Cushing’s disease.
Revenue pressure comes from:
- A small eligible population;
- Hyperglycemia and diabetes risk;
- Strong incumbent competitors;
- New cortisol-pathway therapies;
- Restricted reimbursement;
- Limited label expansion;
- Eventual patent and formulation competition.
The product can remain commercially valuable as a specialty endocrine brand, but it is unlikely to become a major growth driver for Novartis. Its financial trajectory depends on retention of a high-value niche, not broad market penetration.
Key Takeaways
- Pasireotide pamoate is marketed as Signifor LAR by Novartis.
- It is approved for acromegaly and Cushing’s disease.
- The product’s central differentiation is monthly intramuscular delivery and strong SSTR5 activity.
- Hyperglycemia is the principal safety and commercial limitation.
- Cushing’s disease competition has intensified, particularly from osilodrostat.
- Acromegaly competition includes octreotide, lanreotide, and pegvisomant.
- Novartis does not currently disclose a dependable standalone Signifor LAR revenue series.
- The remaining market protection depends on formulation, depot, manufacturing, and method-of-use claims more than on early active-ingredient exclusivity.
- Generic entry is technically and economically more difficult than for an oral small molecule.
- The likely financial path is mature specialty-brand stability followed by gradual erosion, not rapid expansion.
FAQs About Pasireotide Pamoate
Is pasireotide pamoate the same as Signifor LAR?
Yes. Signifor LAR is the Novartis brand containing pasireotide pamoate in a long-acting intramuscular formulation.
Is pasireotide a first-line treatment for acromegaly?
Usually not. It is generally used when surgery is unsuccessful or unsuitable and standard somatostatin analog therapy does not provide adequate biochemical control.
Why does pasireotide cause hyperglycemia?
Pasireotide strongly activates somatostatin receptor subtype 5 and can suppress insulin and incretin signaling. The resulting glucose elevation can be clinically significant.
Does pasireotide have biosimilar competition?
No. Pasireotide is a chemically synthesized small molecule, so the relevant competitive pathway is generic or follow-on injectable competition rather than biosimilar approval.
Which drug is the strongest competitor to pasireotide in Cushing’s disease?
Osilodrostat is one of the most direct competitors because it treats Cushing’s disease through inhibition of cortisol synthesis rather than pituitary somatostatin receptor signaling.
References
- U.S. Food and Drug Administration. (2023). Signifor LAR (pasireotide pamoate) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2012). FDA approves Signifor for Cushing’s disease. https://www.fda.gov
- U.S. Food and Drug Administration. (2014). FDA approves Signifor LAR for acromegaly. https://www.fda.gov
- U.S. Food and Drug Administration. (2018). FDA approves Signifor LAR for Cushing’s disease. https://www.fda.gov
- European Medicines Agency. (2023). Signifor: European public assessment report. https://www.ema.europa.eu
- Novartis AG. (2024). Annual report 2023. https://www.novartis.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent search resources. https://www.uspto.gov
